Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
Clinical Cancer Research (Impact Factor: 7.84). 06/2012; 18(15):4191-200. DOI:10.1158/1078-0432.CCR-11-2936
Source: PubMed

ABSTRACT This study sought to establish whether functional analysis of the ATM-p53-p21 pathway adds to the information provided by currently available prognostic factors in patients with chronic lymphocytic leukemia (CLL) requiring frontline chemotherapy.
Cryopreserved blood mononuclear cells from 278 patients entering the LRF CLL4 trial comparing chlorambucil, fludarabine, and fludarabine plus cyclophosphamide were analyzed for ATM-p53-p21 pathway defects using an ex vivo functional assay that uses ionizing radiation to activate ATM and flow cytometry to measure upregulation of p53 and p21 proteins. Clinical endpoints were compared between groups of patients defined by their pathway status.
ATM-p53-p21 pathway defects of four different types (A, B, C, and D) were identified in 194 of 278 (70%) samples. The type A defect (high constitutive p53 expression combined with impaired p21 upregulation) and the type C defect (impaired p21 upregulation despite an intact p53 response) were each associated with short progression-free survival. The type A defect was associated with chemoresistance, whereas the type C defect was associated with early relapse. As expected, the type A defect was strongly associated with TP53 deletion/mutation. In contrast, the type C defect was not associated with any of the other prognostic factors examined, including TP53/ATM deletion, TP53 mutation, and IGHV mutational status. Detection of the type C defect added to the prognostic information provided by TP53/ATM deletion, TP53 mutation, and IGHV status.
Our findings implicate blockade of the ATM-p53-p21 pathway at the level of p21 as a hitherto unrecognized determinant of early disease recurrence following successful cytoreduction.

0 0
  • [show abstract] [hide abstract]
    ABSTRACT: ATM abnormalities are frequent in chronic lymphocytic leukemia and represent important prognostic factor. Sole 11q deletion does not result in ATM inactivation by contrast to biallelic defects involving mutation(s). Therefore, the analysis of ATM mutations and their functional impact is crucial. In this study, we analyzed ATM mutations in predominantly high-risk patients using: (i) resequencing microarray and direct sequencing; (ii) western blot for total ATM level; (iii) functional test based on p21 gene induction after parallel treatment of leukemic cells with fludarabine and doxorubicin; ATM dysfunction leads to impaired p21 induction after doxorubicin exposure. We detected ATM mutation(s) in 16% (22/140) of patients, and all mutated samples manifested demonstrable ATM defect (impaired p21 up-regulation after doxorubicin and/or null protein level). Loss of ATM function in mutated samples was also evidenced through defective p53 pathway activation after ionizing radiation exposure. ATM mutation frequency was 34% in patients with 11q deletion, 4% in TP53-defected group, and 8% in wild-type patients. Our functional test, convenient for routine use, showed high sensitivity (80%) and specificity (97%) for ATM mutations prediction. Only cells with ATM mutation, but not those with sole 11q deletion were resistant to doxorubicin; concerning fludarabine, this difference was not observed. Interestingly, patients from both these groups experienced nearly identical time to first treatment. In conclusion, ATM mutations either alone or in combination with 11q deletion uniformly led to demonstrable ATM dysfunction in patients with chronic lymphocytic leukemia and mutation presence can be predicted by the functional test using doxorubicin.
    Haematologica 04/2013; · 5.94 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: The prognostic role of ATM defects is well documented in chronic lymphocytic leukemia. However, the predictive value of ATM inactivation is much less understood, even in response to common drugs like fludarabine. It has been demonstrated that CLL cells having inactive ATM exhibit defective phosphorylation of its downstream targets after fludarabine treatment. We performed alternative analysis focusing on fludarabine-induced p53 accumulation and induction of p53-downstream genes after artificial ATM inhibition and, in parallel, using cells with endogenous ATM inactivation. We show that after 24h fludarabine exposure: (i) 5 out of 8 ATM-deficient samples (63%) normally accumulated p53 protein, and (ii) all analyzed ATM-deficient samples (n = 7) manifested clear induction of p21, PUMA, BAX, and GADD45 genes. In all experiments, doxorubicin was used as a confined ATM inductor and confirmed effective ATM inactivation. In conclusion, CLL cells lacking functional ATM appear to have normal response to fludarabine regarding the p53 pathway activation.
    Leukemia & lymphoma 07/2013; · 2.40 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Fludarabine plus cyclophosphamide (FC) is the chemotherapy backbone of modern chronic lymphocytic leukaemia (CLL) treatment. CYP2B6 is a polymorphic cytochrome P450 isoform which converts cyclophosphamide to its active form. This study was conducted to investigate the possible impact of genetic variation in CYP2B6 on response to FC chemotherapy in CLL. Available DNA samples from the LRF CLL4 trial, which compared chlorambucil, fludarabine and FC, were screened by Taqman real-time PCR assays for CYP2B6 SNPs c.516G>T and c.785A>G, which define the most common variant allele (*6). Among the 455 samples that were successfully genotyped, 265 (58.2%), 134 (29.5%) and 29 (6.4%) were classified as *1/*1, *1/*6 and *6/*6, respectively. Patients expressing at least one *6 allele were significantly less likely to achieve a complete response (CR) following FC (odds ratio 0.27; p=0.004) but not chlorambucil or fludarabine. Analysis of individual response indicators confirmed that this inferior response resulted from impaired cytoreduction rather than delayed haemopoietic recovery. Multivariate analysis controlling for age, gender, stage, IGHV mutational status, 11q deletion and TP53 deletion/mutation identified CYP2B6*6 and TP53 mutation/deletion as the only independent determinants of CR attainment following FC. Our study provides the first demonstration that host pharmacogenetics can influence therapeutic response in CLL. This trial is registered as an International Standard Randomised Control Trial, number NCT 58585610 at
    Blood 10/2013; · 9.06 Impact Factor